• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Quince Therapeutics Inc.

    3/24/25 5:21:08 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $QNCX alert in real time by email
    S-8 1 d837482ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 24, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Quince Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   90-1024039

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    611 Gateway Boulevard, Suite 273

    South San Francisco, CA 94080

    (415) 910-5717

    (Address of Principal Executive Offices) (Zip Code)

    Quince Therapeutics, Inc. 2019 Equity Incentive Plan

    Quince Therapeutics, Inc. 2019 Employee Stock Purchase Plan

    (Full title of the plans)

    Dirk Thye

    Chief Executive Officer

    Quince Therapeutics, Inc.

    611 Gateway Boulevard, Suite 273

    South San Francisco, CA 94080

    (415) 910-5717

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Please send copies of all communications to:

    Gordon K. Ho

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, Quince Therapeutics, Inc. (the “Registrant”) is filing this registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) to register the offering of an additional 2,200,082 shares of Common Stock (the “Registered Shares”), par value $0.001 per share (“Common Stock”) of the Registrant. The Registered Shares being registered herein include (i) 1,760,066 shares of Common Stock issuable pursuant to the Registrant’s 2019 Equity Incentive Plan (the “2019 EIP”) and (ii) 440,016 shares of Common Stock issuable pursuant to the Registrant’s 2019 Equity Stock Purchase Plan (the “2019 ESPP”). These additional shares of Common Stock are securities of the same class as other securities for which previous registration statements on Form S-8 were filed with the Commission on May 9, 2019 (File No. 333-231307),  March 16, 2020 (File No.  333-237199), March 1, 2021 (File No. 333-253743),  March 1, 2022 (File No. 333-263186),  March 15, 2023 (File No.  333-270577), and April 1, 2024 (File No. 333-278440) (collectively, the “Prior Registration Statements”). Accordingly, the contents of the Prior Registration Statements are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8. The Registered Shares which represent shares of Common Stock have become reserved for issuance as a result of the operation of the “evergreen” provisions in each of the 2019 EIP and 2019 ESPP, which provide that the total number of shares subject to such plan may be increased on the first day of each Registrant’s fiscal year pursuant to a specified formula.

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    PART II

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by Registrant with the Commission are incorporated by reference into this Registration Statement:

     

      (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 24, 2025; and

     

      (b)

    The description of the Registrant’s Common Stock contained in the registration statement on Form  8-A registering the Registrant’s Common Stock under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) filed with the Commission on May 1, 2019, including any amendments or reports filed for purposes of updating such description, including Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 24, 2025.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    2


    Item 8. Exhibits.

    The following exhibits are filed herewith:

     

              Incorporated by Reference  
    Exhibit
    Number
      

    Exhibit Description

       Form      File No.      Exhibit      Filing Date      Filed
    Herewith
     
     4.1    Amended and Restated Certificate of Incorporation      8-K        001-38890        3.1        5/13/2019     
     4.2    Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective August 1, 2022      8-K        001-38890        3.1        8/1/2022     
     4.3    Amended and Restated Bylaws      8-K        001-38890        3.2        8/1/2022     
     4.4    Specimen Stock Certificate      S-1/A        333-230853        4.1        4/29/2019     
     5.1    Opinion of Cooley LLP                  X  
    23.1    Consent of Cooley LLP (included in Exhibit 5.1)                  X  
    23.2    Consent of Independent Registered Public Accounting Firm                  X  
    24.1    Power of Attorney (included on the signature page of this Registration Statement)                  X  
    99.1    2019 Equity Incentive Plan, and forms of stock award agreements thereunder      10-K        001-38890        10.6        4/1/2024     
    99.2    2019 Employee Stock Purchase Plan      S-1/A        333-230853        10.5        4/29/2019     
    107    Filing Fee Table                  X  

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on March 24, 2025.

     

    QUINCE THERAPEUTICS, INC.

    /s/ Dirk Thye

    Dirk Thye, M.D.

    Chief Executive Officer, Chief Medical

    Officer and Director

    Power of Attorney

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dirk Thye and Brendan Hannah, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated:

     

    Name

      

    Title

     

    Date

    /s/ Dirk Thye

      

    Chief Executive Officer, Chief Medical Officer and Director

    (Principal Executive Officer)

      March 24, 2025
    Dirk Thye, M.D.

    /s/ Brendan Hannah

      

    Chief Business Officer and Chief Operating Officer

    (Principal Financial and Accounting Officer)

      March 24, 2025
    Brendan Hannah

    /s/ David A. Lamond

       Director   March 24, 2025
    David A. Lamond

    /s/ Margaret McLoughlin

       Director   March 24, 2025
    Margaret McLoughlin, Ph.D.

    /s/ Una Ryan

       Director   March 24, 2025
    Una Ryan, OBE, Ph.D.

    /s/ Christopher J. Senner

       Director   March 24, 2025
    Christopher J. Senner

    /s/ Luca Benatti

       Director   March 24, 2025
    Luca Benatti, Ph.D.

    /s/ Rajiv Patni

       Director   March 24, 2025
    Rajiv Patni, M.D.

    /s/ June Bray

       Director   March 24, 2025
    June Bray

     

    4

    Get the next $QNCX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QNCX

    DatePrice TargetRatingAnalyst
    3/24/2025$10.00Outperform
    Oppenheimer
    More analyst ratings

    $QNCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      9/3/24 5:38:44 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      8/22/24 5:51:16 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      8/21/24 6:38:07 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    SEC Filings

    See more
    • SEC Form 8-K filed by Quince Therapeutics Inc.

      8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

      6/5/25 4:12:42 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Quince Therapeutics Inc.

      10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

      5/13/25 8:40:57 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

      5/13/25 8:01:26 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $QNCX
    Leadership Updates

    Live Leadership Updates

    See more
    • Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a total of 65 participants randomized in the study's targeted 86 participants in the six to nine year-old primary analysis population. Key Phase 3 NEAT clinical trial enrollment highlights to date include: A total of 76 participants have been enr

      6/3/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

      Plan to potentially conclude enrollment early for Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline results with existing cash runway Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2025. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "In light of current cash runway and with the goal of maximizing a capital efficient development plan, Quince has made the strategic business de

      5/13/25 8:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics to Present at Citizens Life Sciences Conference

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time. A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event. About Quince Therapeutics

      4/30/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn

      1/23/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. "We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's caliber to our Board of Directors," said David Lamond, chairperson of Quince's Board of Directors. "With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we lo

      2/15/24 7:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Dr. Charles S. Ryan as President

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince. Dirk Thye, M.D., Quince's Chief Executive Officer, said, "Charles is a valuable addition to our management team. His considera

      9/6/23 7:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Financials

    Live finance-specific insights

    See more
    • Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.

      4/5/23 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ryan Una S

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/6/25 5:52:41 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Benatti Luca

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/6/25 5:38:57 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Senner Christopher J.

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/6/25 5:36:21 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Quince Therapeutics with a new price target

      Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00

      3/24/25 8:40:42 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

      SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

      11/14/24 4:00:05 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Quince Therapeutics Inc.

      SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)

      11/13/24 9:17:26 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

      SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

      8/6/24 8:04:44 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care